Microvesicles derived from mesenchymal stem cells inhibit acute respiratory distress syndrome-related pulmonary fibrosis in mouse partly through hepatocyte growth factor

Figure 7 Effects of mesenchymal stromal cell-derived microvesicles on respiratory mechanics and lung functions in acute respiratory distress syndrome pulmonary fibrosis mouse models. A: Pulmonary expiratory resistance; B: Pulmonary compliance; C: Forced expiratory volume in 0.1 seconds (Fev0.1); D: Forced vital capacity (FVC), E: Fev0.1/FVC; F: Pressure of oxygen (PO₂)/oxygen inhalation (FiO₂); G: Transmission and scanning electron microscopy were performed on purified mesenchymal stromal cell-derived microvesicles (MSC-MVs) to reveal their spheroid morphologies and confirm their sizes. ^aP < 0.05, vs the control group; ^bP < 0.05, vs the pulmonary fibrosis group; ^cP < 0.05, vs the MSC-MVs group (n = 6). Control, acute respiratory distress syndrome (ARDS), pulmonary fibrosis, MSC, MSC-MVs and low hepatocyte growth factor (HGF)-MSC-MVs represent the control group, ARDS group, pulmonary fibrosis group, MSC group, MSC-MVs group and low HGF-MSC-MVs group, respectively.